Navigation Links
ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
Date:9/10/2007

netics between ANX-514 (docetaxel emulsion) and the FDA-approved version of docetaxel, marketed under the brand name Taxotere. ANX-514 administered intravenously did not cause hypersensitivity reactions, as opposed to acute hypersensitivity reactions that were observed following intravenous treatment with Taxotere. Antitumor activity of the two products in animal models was similar.

About ANX-514 (docetaxel emulsion)

ANX-514 is a novel nano-emulsion formulation of the chemotherapy drug docetaxel, which is marketed under the brand name Taxotere. ANX-514 is formulated without polysorbate 80 or other detergents and is intended to reduce the severity and/or incidence of hypersensitivity reactions. Docetaxel is an anti-cancer agent that acts by disrupting the cellular microtubular network that is essential for cell division. Immunosuppressant premedication is recommended for docetaxel therapy to reduce the incidence and severity of hypersensitivity reactions. Docetaxel is approved to treat breast, non-small cell lung, prostate, gastric and head and neck cancers.

About Section 505(b)(2)

Section 505(b)(2) of the U.S. Food, Drug & Cosmetic Act (FDCA) allows the FDA to approve a follow-on drug on the basis of data in the scientific literature or conclusions regarding safety or effectiveness made by the FDA in the approval of other drugs. This regulatory pathway potentially makes it easier for drug manufacturers to obtain rapid approval of new forms of drugs based on the FDA's approval of the original drug. Some examples of products that may be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation or indication. Upon approval, a drug may be marketed only for the FDA-approved indications in the approved dosage forms. Further clinical trials are necessary to gain approval for the use of the product for any additional indications or dosage forms. In connection with a Section 50
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...LER TOLEDO recently announced that a free webinar,...ing At-Line Particle Characterization”, will...r, the application of in situ particle characteriz...optimize a series of roller compaction runs while ...action forces. , (PRWEB) ...
(Date:11/19/2009)...RNewswire-FirstCall/ -- Omeros Corporation (Nasdaq...lts for the third quarter ended September 30, 2009...meros reported a net loss of $3.9 million, or $1.3...lion, or $2.54 per share, for the same period in 2... the Company reported a net loss of $15.5 million,...
(Date:11/19/2009)... 19 Spherix Incorporated...or diabetes therapy, and a provider of technical a...ent, biotechnology and pharmaceutical companies, t...ting of Shareholders. ,, At the meeting, shareh...ected the following members to the Board of Direct...
(Date:11/19/2009)...LASIK surgeons and recognized refractive and catar...ns made brought their fellow surgeons up-to-date o...gery, cataract surgery, and ophthalmology in gener...phthalmology (AAO) annual meeting in San Francisco...auber, Dr. David Huang, MD, Dr. Randy Epstein, Dr....
Breaking Biology Technology:Roller Compaction Process Optimization Using At-Line Particle Characterization 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 2Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 3Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 4Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 5Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 6Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 7Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 8Experts Listed at Trusted LASIK Surgeons Bring Peers Up to Date on Vision Correction and Cataract Surgery at Annual AAO Meeting 9
...ts and Manufacturing Process Documentation for Cus...s, BOTHELL, Wash., Nov. 5 BioLife Solutions Inc....nd marketer of proprietary,hypothermic storage and...s,and organs, today announced that it has submitte... Administration (FDA) for the Company,s,HypoThermo...
...ov. 5 RainDance Technologies, Inc.,a provider of ...health and,disease research, today announced that ...uence Enrichment application to The Genome Center ...ne in St. Louis, a world leader,in genomics resear...am, RainDance will provide,its new RDT 1000 and ex...
...v. 5 Environmental Power,Corporation (Nasdaq: EP...today announced that its wholly owned subsidiary, ...ce agreement with Organix, Inc., of Walla,Walla, W...M), using solids,recovered from selected Microgy a...xciting alliance," said Rich Kessel, President and...
Other Biology Technology:BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 2BioLife Solutions Submits FDA Master File on HypoThermosol(R) Preservation and Storage Media for Cells, Tissues 3RainDance Technologies Delivers RDT 1000, Sequence Enrichment Solution to The Genome Center at Washington University School of Medicine in St. Louis 2Environmental Power Corporation and Organix, Inc. Establish Alliance to Produce High Value Soil Amendment Products 2Environmental Power Corporation and Organix, Inc. Establish Alliance to Produce High Value Soil Amendment Products 3Environmental Power Corporation and Organix, Inc. Establish Alliance to Produce High Value Soil Amendment Products 4
(Date:11/20/2009)...acterial gene into yeast, researchers from Delft U...d three improvements in bioethanol production from...acetate and elimination of the major by-product gl...he scientific journal Applied and Environmental M...e by the yeast Saccharomyces cerevisiae from sugar...
(Date:11/20/2009)... of flax shives, and generated from Brassica cari...ich engulf fields in spring, can be used to produc...es carried out by Spanish and Dutch researchers an...ble Energy Reviews . , "These studies evaluate, f... of bioethanol from two, as yet unexploited source...
(Date:11/20/2009)...searchers report that a class of heart medications...ul, effect on the heart, depending on their molecu...journal Circulation Research , found that beta-bl...ors on the heart muscle offer the most benefit to ... beta-receptors can actually undermine the structu...
Breaking Biology News(10 mins):Delft breakthrough in bioethanol production from agricultural waste 2Flax and yellow flowers can produce bioethanol 2Carvedilol shown to have unique characteristics among beta blockers 2CVS Caremark Announces Results of 2009 Health IQ Study 54438 1CVS Caremark Announces Results of 2009 Health IQ Study 54438 2CVS Caremark Announces Results of 2009 Health IQ Study 54438 3AVMA Unveils Improved Online Press Room to Help Journalists 54435 1AVMA Unveils Improved Online Press Room to Help Journalists 54435 2AVMA Unveils Improved Online Press Room to Help Journalists 54435 3Perrigo Company Announces Quarterly Dividend 54432 1
...ated from its wild ancestor more than 8700 years a...rchers in the Mexico,s Central Balsas River Valley...years -- for the presence and use of domesticated ...f Temple University and Dolores Piperno of the Smi...ted their findings in two studies -- "The Cultural...
...Using what they say is a relatively simple method,...r have extracted stem/progenitor cells from testes...ryonic-like stem cells. Researchers say that the n...into any cell type that a body needs, from brain n...roduced these stem cells without the use of additi...
...CellThera, a biotechnology company located in Worc...oengineering Center at Gateway Park, has received ... Projects Agency (DARPA) to extend its research pr...he contract, CellThera, which is part of WPI,s Bio...ll continue their joint efforts aimed at restoring...
Other Biology News:Researchers find the earliest evidence of domesticated maize 2Human adult testes cells can become embryonic-like 2CellThera and WPI advance in regeneration study 2
Porcine IFN-gamma ELISpot Development Kit from R&D Systems
Rattler Plating Beads from Zymo Research
di-3-ANEPPDHQ from Molecular Probes (Invitrogen)
TEMPLIPHI HT SEQ AMPL KIT from GE Healthcare, formerly Amersham Biosciences
Biology Products: